NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

J Natl Compr Canc Netw. 2022 May;20(5):436-442. doi: 10.6004/jnccn.2022.0026.


The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

MeSH terms

  • Adult
  • Anemia* / chemically induced
  • Anemia* / drug therapy
  • Antineoplastic Agents* / adverse effects
  • Hematopoietic Cell Growth Factors / therapeutic use
  • Humans
  • Neoplasms* / drug therapy


  • Antineoplastic Agents
  • Hematopoietic Cell Growth Factors